Table I.

Sequences of primers used in the present study.

mRNA	Primer sequence
RANKL	Forward: 5′-ACCGACATCCCATCTGGTT-3′
	Reverse: 5′-GCCATCCTGATTAACTATTAGTT-3′
OPG	Forward: 5′-AAGCCTTCTCTAACCTCTCC-3′
	Reverse: 5′-GCCCTCGCTTATGATCTGTC-3′
COX2	Forward: 5′-TTGAAATGGCAGTTGATTCCTTT-3′
	Reverse: 5′-TATCCTCTTTCTCAGGGTGCTTG-3′
Piezo1	Forward: 5′-GGCAACATGAGGGAGTTCATTAACTC-3′
	Reverse: 5′-TTCTCCGTCAGGTAGTTGACAATGTG-3′
TRPV4	Forward: 5′-GGCAACTTCCTCACCAAGA-3′
	Reverse: 5′-GGGTATTTCTTCTCTGTCTCT-3′
GAPDH	Forward: 5′-GGCACAGTCAAGGCTGAGAATG-3′
	Reverse: 5′-ATGGTGGTGAAGACGCCAGTA-3′

COX2, cyclooxygenase-2; RANKL, receptor activator of NF-κB ligand; OPG, osteoprotegerin; TRPV4, transient receptor potential cation channel subfamily V member 4.